Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Something interesting just came out of a clinical trial, and it is worth paying attention to. A twice-daily pill called aleniglipron helped overweight adults lose nearly 15% of their body weight. That is almost exactly what the popular weight loss injection semaglutide achieves. For a pill, that is a big deal.
The drug comes from a company called Structure Therapeutics. Their Phase 2b trial results were published in Nature Medicine in June 2026. The study was small, just 85 participants, but the numbers were hard to ignore.
So what exactly happened in the trial? Participants had a body mass index of 27 or above. At the highest dose tested, they lost an average of 14.7% of their body weight. Compare that to Wegovy, the injectable semaglutide, which produced 14.9% weight loss in its major trial. The difference is razor-thin. What surprised researchers most was that aleniglipron performed well at multiple dose levels, not just the highest one. That kind of consistent pattern across doses is a good sign for future development.
The pill works by targeting the same receptor in the body that injectable GLP-1 receptor agonist drugs like Wegovy and Ozempic target. The difference is delivery. No needles, no refrigeration, no special training needed. Patients simply take it twice a day by mouth. For people who are uncomfortable with injections or who live in areas with limited healthcare access, that could be a genuine advantage.
Now, before getting too excited, there are real limitations here. A trial of 85 people is not large enough to show the full picture. It confirmed the weight loss effect. It could not reliably show how often side effects occur across a bigger population. Nausea and vomiting are common problems with GLP-1 drugs as a class. One large analysis looked at data from over 27,000 patients across 48 trials. It found that about 21% experienced nausea and around 9% experienced vomiting. These side effects are often why people quit these trials early. A much larger Phase 3 study will need to track these issues far more carefully.
There are also practical design challenges ahead. Because the pill is taken twice a day in a blinded trial, tracking whether patients actually take it correctly is harder than with a weekly injection. Researchers need clear rules about what counts as a missed dose versus a protocol violation. Those rules need to be written into the trial design upfront, not figured out later.
Timing matters too. The FDA’s January 2025 guidance on weight loss drugs sets a specific bar. Any new treatment must show at least 5% more weight loss than a placebo, measured after a full year of maintenance dosing. That is not the same as measuring results right after dose escalation. Phase 3 trial designers need to plan around that maintenance window specifically. Otherwise, the results may not satisfy regulators, regardless of how promising they look on paper.
On the competitive side, there is some urgency. Oral semaglutide already exists under the brand name Rybelsus, but it was approved for type 2 diabetes, not obesity, and at lower doses. The field of oral GLP-1 drugs for weight management is still wide open. Structure Therapeutics holds a U.S. patent on the core chemical structure of aleniglipron, granted in March 2024. That gives them some protected runway, but only if they move quickly and run a tight Phase 3 program before rivals catch up.
The company has not yet shared the detailed design for its Phase 3 trial. Once that becomes public, it will be clearer whether the team has built a study that can satisfy the FDA’s current standards for obesity drugs. The Phase 2b data gives aleniglipron a strong starting point. Whether it translates into an approved treatment for obesity depends entirely on what comes next.
